Akiko Ogawa

The paper shows that modified adenosines from RNA catabolism are sequentially metabolized to prevent toxicity and maintain metabolic balance.

The paper identifies a novel A3R-selective ligand and reveals structural insights into A3R activation, enabling structure-guided engineering of m6A-insensitive A3R for drug discovery.

The paper identifies m6A as an endogenous ligand for the A3 adenosine receptor, showing it has higher affinity than unmodified adenosine and plays a role in type I allergy.